This live web event has ended. Thank you for attending.
The co-formulation of biologics, particularly “cocktails of monoclonal antibodies (mAbs)”, is gaining lot of interest within the Pharmaceutical Industry as evidenced by increasing number of active clinical trials and recent regulatory approvals of several co-formulated biologics products. Mixing different therapeutic proteins could adversely affect their stability, and reduce the shelf life of each individual component, making the control of such products very challenging. It remains unclear to what extent mAbs with different physicochemical properties can be combined in solution without detrimental effects on protein stability. There are very few published articles on the topic with limited knowledge and information to the scientific community.
During this webinar, we will discuss outstanding challenges and opportunities for the co-formulation and stabilization of mAb combinations. While we present a few co-formulation case studies, the attendees will also hear about orthogonal analytical methods that are appropriate for the characterization of mAb mixtures.
The content of the webinar will be highly relevant for scientists and managers involved in the development of antibody drugs.
- Learn about co-formulations of therapeutic antibodies
- Understand challenges in developing antibody co-formulations
- Get acquainted with analytical approaches to study antibody stability in co-formulations